JP Morgan Upgrades Apellis Pharmaceuticals to Overweight, Raises Price Target to $81
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anupam Rama has upgraded Apellis Pharmaceuticals from Neutral to Overweight and raised the price target from $60 to $81.
October 06, 2023 | 10:57 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Apellis Pharmaceuticals has been upgraded to Overweight from Neutral by JP Morgan, with a raised price target of $81, up from $60.
The upgrade from JP Morgan is a positive signal for Apellis Pharmaceuticals. It indicates that the analyst believes the company's stock will outperform the market or its sector in the short term. The raised price target also suggests that the analyst sees significant upside potential for the stock. This could lead to increased investor interest and potentially a rise in the stock's price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100